Short answer
10x Genomics, Inc. (TXG) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $149M (down 1.7% year over year) with net income of −$27M.
Q3 2025 key financials · XBRL
- Revenue
- $149M
- −1.7% YoY · −13.8% QoQ
- Net income
- −$27M
- +23.2% YoY · −179.5% QoQ
- Operating margin
- -21.6%
- Gross margin
- 67.3%
- EPS (diluted)
- −$0.22
- +24.1% YoY · −178.6% QoQ
Source: XBRL data from the 10x Genomics, Inc. (TXG) Q3 2025 10-Q on SEC EDGAR. USD.
10x Genomics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New acquisition risk from Scale Biosciences asset acquisition in August 2025 with $20M technology transfer payment due Q1 2026 and up to $30M contingent consideration
- Material update on patent litigation settlements with Vizgen and Bruker, generating total $94M upfront with gain on settlements boosting first-half 2025 revenues
- Regulatory advantage from July 2025 OBBBA tax law restoring immediate R&D expense deductibility, reducing income tax expense by $3.3M for nine months ended September 2025
- Market risk from 37-40% decline in instruments revenue for recent periods offset partially by 1-2% growth in consumables sales impacting near-term sales performance
- Liquidity risk from operating losses and $1.5B accumulated deficit despite $482M cash balance; potential future funding needs due to cash burn and contingent acquisition payments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 10x Genomics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.